Abstract | Although at the genetic level cancer is caused by diverse mutations, epigenetic modifications are characteristic of all cancers, from apparently normal precursor tissue to advanced metastatic disease, and these epigenetic modifications drive tumour cell heterogeneity. We propose a unifying model of cancer in which epigenetic dysregulation allows rapid selection for tumour cell survival at the expense of the host. Mechanisms involve both genetic mutations and epigenetic modifications that disrupt the function of genes that regulate the epigenome itself. Several exciting recent discoveries also point to a genome-scale disruption of the epigenome that involves large blocks of DNA hypomethylation, mutations of epigenetic modifier genes and alterations of heterochromatin in cancer (including large organized chromatin lysine modifications (LOCKs) and lamin-associated domains (LADs)), all of which increase epigenetic and gene expression plasticity. Our model suggests a new approach to cancer diagnosis and therapy that focuses on epigenetic dysregulation and has great potential for risk detection and chemoprevention.
Even before the discovery of epigenetic mod ifications in cancer, classical tumour biology suggested that generalized disruption of gene expression might underlie the key proper ties of unregulated tumour growth, invasion and metastasis. Perhaps the earliest person to recognize the importance of gene expres sion in cancer was Sidney Weinhouse, who described a generalized disruption of the biochemistry of cancer cells that was focused on isozymes that were primarily related to metabolism 1 . However, since the discovery of oncogene mutation in human tumours 2 , the principal focus of cancer genetics has been on mutations. We argue in this Opinion arti cle that, although key mutational changes are necessary for the initiation of what we cur rently recognize as neoplastic growth and are likely to be required for escape from a cellular niche, epigenetic modifications also have a crucial role: these modifications allow rapid cell ular selection in a changing environment, thus leading to a growth advantage for the tumour cells at the expense of the host. This view does not contradict and indeed col laborates with the genetic model, but it puts epigenetics at the very heart of cancer biol ogy, from normal precursor cells at the sites where cancer arises, and through all stages of tumour progression, to advanced metastatic disease.
The first experiments on DNA methy lation in human cancer, which compared samples of human colorectal cancer with matched normal mucosa isolated from the same patients, showed widespread hypomethy lation involving approximately onethird of singlecopy genes 3 . In response to the discovery of tumour suppressor genes 4 , later studies focused on identifying silenced genes as surrogates for mutation, beginning with the observation of promoter hypermethylation of RB1 by Horsthemke and colleagues 5, 6 . During the 2000s, the maturation of microarrays and the advent of nextgeneration sequencing technologies in combination with the rise of datadriven discovery in biology have led to important new insights. These include the discovery of genomewide loss of epigenetic stability, which is common across disparate tumour types. This seems to be the underlying mech anism for both the hypomethylation and the hypermethylation of individual genes, which was the historical focus of this field 7 . In addi tion, recently discovered mutations in the epigenetic apparatus probably contribute to epigenetic disruption in cancer. We review these recent discoveries and point to the possibility that cancer is a state in which the epigenome is allowed to have greater plas ticity than it is supposed to have in normal somatic tissues. This increased epigenetic plasticity is a normal component of develop ment or postnatal responses to injury, but its constitutive activation in cancer causes epige netic heterogeneity that leads to most of the classical cancer hallmarks. We discuss below how this perspective provides new research avenues for diagnostics and treatment.
Large epigenetic structures
Just as the field of cancer epigenetics was presaged by early studies of abnormal gene expression, the role of large epigenetic structures in cancer was indicated by the earliest studies of cancer epigenetics by Theodor Boveri, who described abnormal chromatin in cancer cells in photomicro graphs in 1929 (REF. 8 ). Alterations in nuclear shape are often used for diagnosis and are potentially symptomatic of the disorganiza tion of this carefully regulated state 9 . In addi tion, nuclear lamina proteins (which serve to retain nuclear organization) show altered gene expression in cancer 10 . We describe below advances from wholegenome ana lyses that begin to provide molecular detail to these altered structures in cancer.
Chromatin LOCKs and LADs. Euchromatin refers to genes that are more open to tran scription owing to posttranslational modi fications of histones and lower nucleosome density, whereas heterochromatin is the oppo site: genes that are less open to transcription owing to greater nucleosome density and certain posttranslational histone modifica tions. Typically, facultative heterochromatin -that is, a region that can switch between transcriptionally repressive states and acti vated states -is examined at a local gene level. However, in addition to smallscale changes, the genome is partitioned into large euchromatic and heterochromatic domains, which have been given different names for mostly overlapping structures by laborato ries that have approached this organization using varying methods. We recently reported large organized chromatin lysine modifications (LOCKs), which are defined by genomic domains enriched for heterochromatin post translational modifications, such as histone H3 lysine 9 dimethylation (H3K9me2) 11 . LOCKs expand during differentiation and are lost in cancer 11 (FIG. 1a, b) . Heterochromatic regions can also be defined by their organiza tion and position within the nucleus: DNA sequences associated with proteins in the nuclear lamina are known as lamina-associated domains (LADs) 12 . Heterochromatic regions defined by histone modifications (LOCKs) and those defined by nuclear location (LADs) have been shown to have 80% overlap in dif ferent samples 11, 13, 14 , but a causal relationship, as in LADs controlling chromatin or chro matin informing nuclear location, has not yet been proved.
LOCKs and LADs change during develop ment, generally increasing in size. Genes in LADs are typically transcriptionally repressed 15 , but by artificially reorganizing the nucleus to move genes to the nuclear periphery, transcription profiles and his tone modifications of chromatin contain ing these genes are drastically altered 15 . Genes encoding proteins that are involved in organizing the nuclear membrane also have altered expression in many different cancer types 16 . Different laboratories have observed dynamic changes in chromatin state by examining different histone sitesfor example, H3K9me2, H3K9 trimethyla tion (H3K9me3) or H3K27me3 -but still note that the prevalence of heterochromatic regions is associated with the differentiation state of the cell 17, 18 . LOCKs are also altered in cells undergoing epithelial-mesenchymal transition (EMT), an important behaviour in cancer progression: during EMT, chromatin is reprogrammed in bulk, which results in a dramatic loss of H3K9me2 and an increase of H3K4me3 and H3K36me3 (REF. 19 ). Chromatin immunoprecipitation followed by microarray (ChIP-chip) experiments carried out on mouse chromosomes 4-14 showed loss of H3K9me2 in 96% of LOCKs but not in nonLOCK regions 19 . 
Hypomethylated blocks.
We recently made a surprising discovery by using wholegenome bisulphite sequencing of human colorectal cancer samples, and this finding helps to explain the earliest observation in cancer epigenetics: the widespread hypomethylation of genes in cancer 3 . By comparing three sam ples of colorectal cancer to matched normal mucosa from the same patients, we identified long blocks of hypomethylated DNA in can cer with a median size of 28 kb and a maxi mum size of 10 Mb (a range of 5 kb-10 Mb) 7 (FIG. 1a,b) . In blocks, normal samples exhib ited methylation levels of ~80%, and the cancer samples ranged from 40% to 60%. Onethird of transcriptional start sites are contained within the large hypomethylated blocks. Furthermore, these hypomethylated blocks mostly corresponded to LOCKs and LADs, uncovering a surprising relationship between large nuclear domains of both DNA and chromatin that are disrupted in cancer 7 . These findings were subsequently confirmed by others 22 .
There is a point of confusion in the lit erature that we wish to clarify: in older literature based on Southern hybridization of long interspersed nuclear element (LINE) or Alu sequences, it seems that the DNA hypo methylation in cancer is due to repetitive sequences and not to singlecopy genes 23 . However, modern wholegenome bisulphite sequencing methods have demonstrated that repetitive sequences, although somewhat enriched in hypomethylated blocks, are in fact no more hypomethylated than nonrepetitive sequences in the blocks 7 .
What is the potential role of hypomethy lated blocks in cancer? An intriguing sug gestion comes from an analysis of gene expression. Although the overall level of gene expression in hypomethylated blocks remains low in cancer, the hypomethylated blocks contain the most variably expressed genes in tumours compared with normal controls 7 . Furthermore, the DNA methy lation levels in these regions were not only reduced, they were also extremely variable in the quantitative levels of DNA methy lation 7 . Thus, although mean changes in gene expression and DNA methylation in cancer are important, their heterogeneity may be equally or even more important in tumour heterogeneity and cancer progression and may underlie tumour cell heterogeneity.
Furthermore, similar structures -known as partially methylated domains (PMDs) -have been found to be relevant in dif ferentiation and reprogramming. PMDs are large regions that are differentially methy lated between embryonic stem cells and fibroblasts 24 , as well as between induced pluripotent stem (iPS) cells and fibroblasts 25 . These areas generally overlap with the blocks found in cancer 7 and are hypomethylated in more differentiated cells. This reinforces the idea that there is a strong link between the epigenetic loci dysregulated in cancer and the loci that show controlled alteration in differentiation.
In addition, the hypomethylated blocks may contribute to mutation. Hypomethylated loci in cancer often coordinate with DNA break hotspots, and may therefore contribute to copy number changes 26 . As these primary observations are so new, it is likely that addi tional mechanisms linking these considerable regional DNA methylation changes to cancer will be uncovered over time.
5hydroxymethylcytosine . New singlebaseresolution methods that are sensitive to hydroxymethylation are emerg ing to aid in distinguishing differences in hydroxymethylation from total methylation in cancer 32, 33 .
Small epigenetic structures
The role of DNA methylation in smaller regions of DNA, such as CpG islands (CGIs), is part of the classical cancer epigenetics literature, but here too our perspective has been greatly changed by the advent of newer genomic technologies. For example, the existence of CpG island shores (CGI shores) and of asymmetric division of nucleosomes during DNA replication were unknown until recently.
CGIs and shores. In 1982, Wolf and Migeon 34 discovered highly CpGenriched sequences that, when methylated on the inactive X chromosome, are associated with silencing of housekeeping genes. Bird and colleagues 35 later identified what they termed islands of CpGrich sequences enriched at genes throughout the genome.
The observation of the hypomethylation of genes in human colorectal cancer 3 was extended shortly thereafter to a larger series of tumours, including premalignant adeno mas, with hypomethylation as an apparently ubiquitous feature of cancer 36 (FIG. 1a,b) . The overall global reduction of 5methylcytosine in tumours was confirmed by quantitative highperformance liquid chromatography (HPLC) 37 . Many laboratories identified genes activated by hypomethylation, includ ing oncogenes, such as HRAS 38 , and the families of genes expressed normally in testis and aberrantly activated in tumours, such as the melanomaassociated antigen (MAGE) family in melanoma 39 . Additional highthroughput arraybased methods have identified hundreds of genes that are epigenetically activated in various cancers, including lung, gastric, colon, pancreatic, liver and cervical cancers [40] [41] [42] [43] [44] [45] [46] [47] [48] . Arguing that epigenetic gene silencing might involve tumour suppressor genes, in 1991 Horsthemke 5 and Dryja 6 indepen dently identified hypermethylation of a CGI upstream of the RB1 tumour suppressor gene 5, 6 . Many tumour suppressor genes have since been associated with hypermethy lated CGIs 49 (FIG. 1a,b) . However, there are several conundrums in this work. One issue is that much of this research was dedicated to the analysis of stable tumour cell lines and with the ability to differentiate into euchromatin and hypomethylated genes, or into heterochromatin and hypermethylated genes. Our argument is that epigenetic dysregulation allows for selection in response to the cellular environment for cellular growth advantage at the expense of the host. Mechanisms include mutations in epigenetic regulatory genes (for example, DOT1-like (DOT1L), mixed lineage leukaemia (MLL), EP300 (which encodes p300) and tet methylcytosine dioxygenase 2 (TET2)) and primary epigenetic modifications with positive feedback. c | Loss of boundary stability of methylation at CpG islands includes the encroaching of boundaries, leading to CpG island hypermethylation, and the shifting out of boundaries, leading to hypomethylated CpG shores. Both mean shifts in methylation and hypervariability allow for selection.
immortalized cell lines, which show marked hypermethylation of CGIs in general 50 . Furthermore, as Bestor and others [51] [52] [53] have repeatedly pointed out, most hypermethy lated tumour suppressor geneassociated CGIs are not in the promoters of these genes, and thus the hypermethylation of these sequences is likely to be consequential rather than causal [51] [52] [53] . It has been proposed that a priori methylation is a mechanism of tumour suppressor gene silencing that can cause cancer predisposition (rather than being a late event in tumorigenesis) in a simi lar manner to the cancer predisposition that is caused by germline mutations; however, the data supporting this have been relatively sparse 51 . The most exciting example is MLH1 methylation transmitted as a germline trait, but this report was repudiated by most of its authors owing to contamination of the germ cells with stroma 54, 55 . Indeed, we believe the mechanism of tumour suppressor gene silencing to be primarily driven by chromatin modification and not by DNA methylation. Vogelstein and colleagues 56 showed in 2003 that tumour suppressor gene silencing seems to be driven by histone modifications before DNA methylation changes 56 . Recently, Sproul and colleagues 57 directly showed that DNA hypermethylation of tumour suppressor genes in breast cancer occurs at sites that are already repressed in normal cells of the same lineage 57 . The same group extended these convincing results regarding the lack of a role for DNA hypermethylation in cancer development to 1,154 human cancer samples from seven different tissue types 58 . Similar findings at individual loci have also been shown by others 52, 53 .
Loss of CGI boundary stability in cancer.
With the advent of wholegenome epigenetic analysis, it was possible to broaden the focus of cancer epigenetics to consider regions out side the relatively limited CGIs. We designed a microarray using an algorithm that is agnostic to genes and CGIs 59 , and found that most methylation differences between tissues (tissue-specific differentially methylated regions (tDMRs)) occurred outside CGIs, often within 2 kb of CGI boundaries in regions that are now commonly referred to as CGI shores 60 . A retrospective analysis of previous work agrees with this result; tDMR loca tions are more common in lowCpGdensity promoters, although the connection to CGI shores was not identified 24 . Furthermore, compared with the fibro blasts of origin, 70% of altered methylation regions (reprogramming-specific differentially methylated regions (rDMRs)) in iPS cells are located in CGI shores. This suggests that shores are important for differentiation and reprogramming 61 . Indeed, colon cancer can in most cases be distinguished from normal colon tissue using these rDMRs, suggesting that carcinogenesis may involve a partial reprogramming of the epigenome towards a more stem celllike state 61 .
What is the function of CGI shores? One possibility is that they are sites of alternative transcription and enhancer binding regions; this is in contrast to CGIs, which Wolf and Migeon 34 and others demonstrated are strongly protected from DNA methylation to maintain housekeeping gene function 34 . Indeed, hypomethylated CGI shores were shown to activate alternative transcriptional start sites proximate to cancer-specific differentially methylated regions (cDMRs), as shown by 5ʹ rapid amplification of cDNA ends (RACE) experiments 60 .
Another clue to the function of CGI shores comes from wholegenome bisul phite sequencing. Cancers lose the sharply demarcated boundary between high and low methylation that is defined by CGIs; that is, at the CGI shores 7 . Thus, when the boundary between high and low methy lation shifts inwards towards the CGI, the CGI shore becomes hypermethylated. When the boundary shifts outwards, the CGI shore becomes hypomethylated (FIG. 1c) . The ero sion of these sharply defined boundaries results in altered gene expression 7 .
Glossary

Bivalent modifications
Nucleosomes containing both euchromatic histone H3 lysine 4 trimethylation (H3K4me3) and heterochromatic H3K27me3 post-translational modifications.
Cancer hallmarks
Ten biological properties of cancer that are said to define the disease; we argue that they arise by natural selection for cellular survival at the expense of the host in the setting of epigenetic dysregulation and random variation.
Cancer-specific differentially methylated regions (cDMRs). Differentially methylated regions that distinguish cancer cells from normal cells.
Chemoprevention
Administration of pharmacological compounds to reduce cancer incidence without certain knowledge of its effect on a given patient.
CpG islands
(CGIs). Areas of high CpG dinucleotide density in the genome, typically defined as a region at least 200 bp long with >50% GC dinucleotides and an observed-to-expected CpG ratio of >0.6.
CpG island shores
(CGI shores). The region 2 kb on either side of a CpG island, and the location of most cancer-specific, tissue-specific and reprogramming-specific differentially methylated regions.
Epigenetic dysregulation
The loss of normal control of DNA methylation or chromatin as a result of injury, epigenetic change or mutation, leading to phenotypic drift.
Epigenetic variability
Increased inter-sample variation in the methylation or chromatin state. This was recently identified as a common property of cancer, allowing for more accurate detection between samples.
Euchromatin
Areas of the genome that are more open to transcription owing to post-translational modifications of histones and with less nucleosome density.
Heterochromatin
Areas of the genome that are less open to transcription owing to post-translational modifications of histones and with greater nucleosome density. Facultative heterochromatin can change between the two states. Large organized chromatin lysine modifications and lamina-associated domains describe heterochromatin over relatively large regions and are associated with the nuclear membrane.
Hypomethylated blocks
Large (mean 144 kb) regions that are broadly hypomethylated in cancer and that mostly overlap with large organized chromatin lysine modifications and lamina-associated domains.
Lamina-associated domains
(LADs). Genomic regions located in the nuclear periphery that are associated with lamina (an inner nuclear membrane-associated protein) and usually have low expression levels.
Large organized chromatin lysine modifications (LOCKs). Large heterochromatic regions characterized by low gene expression that are altered between somatic and stem cells; they are typically lost in cancer cells.
Loss of imprinting
(LOI). Loss of parent of origin-specific expression in cancer of imprinted genes, first observed for insulin-like growth factor 2 (IGF2) in Wilms' tumour and colorectal cancer.
Ornstein-Uhlenbeck process
An overdamped Brownian harmonic oscillator -that is, stochastic variation from a normal state with no persistence of the rate of change -opposed by a stronger restoring force towards the equilibrium point. We are using this to model stochastic change in DNA methylation.
Reprogramming-specific differentially methylated regions (rDMRs). Differentially methylated regions that distinguish reprogrammed stem cells from somatic cells.
Tissue-specific differentially methylated regions (tDMRs). Differentially methylated regions that distinguish normal tissues from each other.
Furthermore, a striking hypervariability in DNA methylation is found at these CGI shores or boundaries in cancer samples, similar to the hypervariability of DNA methy lation described above for the large blocks 7 (FIG. 1c) . This same property of hyper variable DNA methylation at the CGI shores or boundaries and blocks is a general property of cancer, affecting at least breast, colorectal, kidney, lung and thyroid tumours 7 . Tissue heterogeneity does not explain this hypervari ability because normal tissue displays even greater heterogeneity than cancer samples 7 . In fact, an increase in methylation hypervariabil ity in phenotypically normal tissue is predic tive of future cancer development 62 . A similar hypervariability is found in gene expression in cancer 63 , and the most hypervariable of these genes are found within the large blocks 7 . We emphasize that mean changes in gene expres sion are important but that variance may be equally important in tumour progression.
Small chromatin domains. Individual nucleo somes, as opposed to the large domains described above, are also likely to be involved in affecting tumour progression. The organi zation of chromatin into euchromatic and heterochromatic structures is controlled by nucleosome positioning, which functions together with posttranslational modifica tions of histone tails (for example, in enhanc ers) 64, 65 . Physical access to DNA is restricted by nucleosome positioning and packing -chromatin remodelling complexes act to alter this in cancer 66 . For example, transcrip tional activity is associated with nucleosome depletion 67 , with transcriptionactivating histone modifications such as acetylated H3K14 (REF. 68) and with the presence of specific histone variants such as H3.3 (REF. 69 ) and H2A.Z 70 . It is important to consider the complex combinatorial nature of the histone code; different histone modifications often act together, meaning that each modification must be considered in context with the other modifications that are present on the nucleo some 71 . Some regions are even bivalent, with nucleosomes having both H3K4me3 (a euchromatic, transcriptionally active modification) and H3K27me3 (a heterochro matic, repressive modification), implying a metastable pluripotent state 72 . Although previous work has demonstrated that bivalent modifications do not occur on the same his tone tail 73 , more recent work has shown that these opposing modifications localize to a single nucleosome, with repressive and acti vating marks on different H3 proteins within the same nucleosome 74 . These same regions are associated with hypermethylated CGIs in cancer 75, 76 (FIG. 1a,b) and reprogramming 61 , and in fact a relationship has been shown between DNA methylation and nucleosome positioning 77 and histone modification 18 . We and others 78, 79 have identified one mechanism for heterochromatininduced silencing of tumour suppressor genes. Antisense expression of cyclindependent kinase inhibitor 2B (Cdkn2b, which encodes p15) generates heterochromatin formation at the sense promoter, leading to gene silencing, and this mechanism seems to be important in leukaemia 78, 79 . Hypermethylation ensues on cell differentiation, and the expression of antisense RNA has been shown to act as a mediator of chromatin remodelling and heterochromatin formation (FIG. 1a,b) . Intriguingly, CGI hypermethylation does occur but only arises after heterochromatin formation 79 . Cisacting noncoding RNAs at promoters and enhancers can regulate chro matin at gene promoters 80 . The observation of chromatin modifications preceding DNA methylation during differentiation resonates with the observations that CGI hypermethy lation arises secondarily to chromatin modifications in tumour suppressor gene silencing 56 , and that the hypermethylated CGIs in cancer are located at genes that have already been silenced in normal tissue 57, 58 , presumably through chromatin.
Mutations and the epigenome
The recent discovery of several mutated epigenetic modifiers in human cancer pro vides a potential mechanism by which DNA mutation might lead to epigenetic alterations. Given the apparently universal presence of DNA methylation and chromatin alterations in human cancer, we summarize below the frequency of mutations of epigenetic modify ing genes, going gene by gene and tumour by tumour, beginning with the Catalogue of Somatic Mutations in Cancer (COSMIC) database 81 and then reviewing the original citations. The classes of genes include histone variants (direct substitution of a mutant his tone isoform); DNA methyltransferases; histone acetyltransferases; histone deacety lases; histone methyltransferases; histone demethylases; and chromatin remodel ling factors, which can induce changes in euchromatin and heterochromatin (TABLE 1) . Mutations in chromatin readers are also occa sionally involved in cancer but apparently not as drivers of cancer progression 82 . Our analysis of the mutation frequency of epigenome modifiers in cancer reveals a surprising pattern. Although there is clearly a relationship between mutations and epi genetic modification in cancer, most of the epigeneticassociated mutations in solid tumours identified to date involve either rare aggressive variants of adult tumours or paediatric cancers. For example, the com mon form of pancreatic adenocarcinoma shows an 8% mutation frequency in the histone acetyltransferase p300 (EP300) 83 , but the rarer pancreas neuroendocrine cancer has a 44% frequency of the histone methyl transferase multiple endocrine neoplasia I (MEN1) 84 (TABLE 1) . Similarly, childhood glioblastoma, an extremely rare brain cancer, shows frequent (35.6%) mutations in histone H3 family 3A (H3F3A), but adult glioblas tomas show a drastically lower frequency of H3F3A mutations (3.4%) 85 (TABLE 1) .
By contrast, haematological cancers frequently involve chromosomal rearrange ments of epigenetic modifiers, and this has been known for many years; for example, in mixedlineage leukaemias 86 . Acute myeloid leukaemia involves mutations in several genes encoding proteins that modify DNA methy lation, including DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 1 (IDH1) and IDH2. These mutations lead to either decreases in DNA methylation (IDH1 and IDH2 mutations) or increases in DNA methylation (DNMT3A mutations) [87] [88] [89] . Chronic myelomonocytic leukaemia involves mutations in tet methylcytosine dioxyge nase 2 (TET2), which is involved in DNA demethylation 90 . Lymphomas involve fre quent inactivating mutations in the histone acetyltransferases EP300 and CREB bind ing protein (CBP; also known as CREBBP), leading to increased heterochromatin and resulting in gene silencing 91, 92 . The histone methyltransferase mixedlineage leukaemia (MLL), which undergoes translocations as a defining characteristic of mixedlineage leukaemia, functions through DOT1like (DOT1L), an H3K79me2 methyltransferase, which leads to specific gene activation 93 . Epigenetic mutations also frequently occur in cancers that relapse or that are otherwise resistant to therapy, such as muta tions of CBP in relapsed ALL 94 . A detailed analysis of these mutations can be found in paediatric glioblastoma, thus preventing H3.3K27 modifications 85, 95 . Such a mutation would be expected to substantially affect chromatin structure, causing aberrant gene expression and potentially allowing for the acquisition of aggressive properties; it should be noted that adult glioblastomas do not frequently contain this mutation. A similar argument can be made for ovarian clear cell carcinoma -mutations in the chromatin remodeller ARID1A were found to be com mon in this aggressive subtype in two differ ent studies (57% and 46% frequency) 96, 97 but were not present in highgrade serous ovarian carcinoma 97 .
A very important possibility in consider ing the relationship between DNA mutations and epigenetic modification in cancer is that altered DNA methylation or chromatin modifications may change the mutation rate itself. For example, guanine quadruplexes (G4s) increase the risk of DNA breakage and activation of the homologous recombination DNA repair pathway; these breaks are inhib ited by DNA methylation. Hypomethylated loci in cancer often coordinate with DNA break hotspots, and these are enriched in G4s 26 . Methylationmediated mutation through spontaneous deamination may also give rise to mutation; 18.2% of inherited gene mutations occur as C-G>T-A mutations in CpG dinucleotides 98 ; C-G>T-A mutations also make up the bulk of substitutions in many cancers 99 , even specifically at CpG dinucleotides in some cases 83 . More substan tially, chromatin state has been shown to cor relate extremely well with somatic mutation rate: H3K9me3 levels alone are predictive of >40% of somatic mutation loci in human cancer samples 100 . Common DNA fragile sites, which are implicated in copy number variation in cancer, also have decreased sta bility in regions of heterochromatin 101 . The organization of chromatin and genetic archi tecture of the nucleus have a direct effect on the rate and effectiveness of copy number alterations and rearrangements in cancer 102 . These data represent clear correlations between areas of epigenetic dysregulation and mutation, suggesting a collaborative effort between epimutation and genetic mutation in cancer development.
Abnormal expression of epigenetic modifier genes.
It is also important to note that many alterations in the expression of epigenetic modifiers have been reported, and some of these seem to have an important role in tumour progression (and have been reviewed extensively elsewhere 64, 65, 103 ). Perhaps the most notable example is over expression of enhancer of zeste homo logue 2 (EZH2), which results in increased H3K27me3 levels and thus silences tumour suppressor gene expression and promotes metastasis 104 . Therefore, these alterations in the epigenetic machinery are more complex to understand, and they should be viewed not as equivalent to the mutations sum marized in TABLE 1 but rather as members of a positive feedback loop that leads to epigenetic dysregulation. An example of a positive epigenetic feedback loop in malig nant transformation has recently been dem onstrated directly in the nuclear factorκB (NFκB) pathway 105 . Another example is the class of reprogramming factors that lead to the generation of iPS cells 106 . We have also observed a significant overlap of rDMRs and cDMRs 61 . Furthermore, many of the repro gramming genes are overexpressed in can cer 107 . A nonexhaustive list of examples of alterations in gene expression of epigenetic modifiers in cancer is provided in TABLE 2. One lesson from examining the expression of epigenetic modifiers in cancer is that the balance of euchromatic and heterochromatic histone modifications is crucial -a modi fication too far in either direction towards euchromatin or heterochromatin leads to dysregulation of gene expression and is advantageous for tumour growth (see REF. 108 for an example). This imbalance could be a target for therapy: for example, histone modi fications could be brought back into balance through smallmolecule inhibitors of histone deacetylases, histone acetyltransferases or histone methyltransferases 108 .
Cancer as epigenetic dysregulation
In summary, most cancers may share sev eral common epigenetic modifications: largescale alterations in chromatin involv ing LOCKs or LADs and hypomethylated blocks, and loss of methylated boundary stability at CGIs leading to hypermethy lated CGIs, hypomethylated CGI shores and aberrant gene expression. This would lead to a drift towards a hybrid stem-somatic cell state, with increased methylation of Polycomb target regions and loss of methy lation at pluripotency loci. A simple unifying explanation of these results is that cancer is caused by epigenetic dysregulation, which could account for the high degree of pheno typic variability that is observed among indi vidual cancers and that leads to selection for cancer cell survival independent of the host.
To visualize this process, consider the classic 'epigenetic landscape' described by Waddington 109 , by which the normal epige netic signature of the cell is represented by a ball trapped in a valley, the walls of which represent a restoring force constraining the ball in its normal state (FIG. 2a) . Although this signature differs among tissues, it is highly regulated, invariant among individuals and ultimately defined genetically, according to the classic view 109 . In order to be dynamic and flexible, the epigenetic signature must allow for variation, provided in the form of intrinsic noise: that is, a biochemical char acteristic of the system that leads to random departure from a set point 110 .
For example, methylation inheritance shows an error rate that is estimated to be 4% for a given CpG motif per cell division in a cell population 111 . This is also consistent with the idea that epigenetic variability can lead to phenotypic selection on a much shorter timescale than can mutation 112 . Furthermore, variation in the epigenome may be controlled by factors in the genetic code, providing a potential mechanism for control of the level of this variation (which is represented by the slope of the valley walls) 113 . In cancer, an initial dysregulation of the epigenome would flatten this valley, break ing the delicate balance of regulation that maintained the stable epigenetic signature in the face of noise (FIG. 2b) . This could be the result of repeated restructuring of the epigenetic landscape through inflammatory insult, as in the case of Barrett's oesopha gus 114 , or it could be through an initial muta tion in one of the genes directing the fragile balance of the epigenome (almost any of the mutations presented in TABLE 1). A splicing variation in an epigenetic modifier gene could also cause dysregulation. For example, an isoform of DNMT3B commonly found in cancer, DNMT3B7, results in increased vari ation in the methylation signature 115 . Even the classical 'gatekeeper' mutations may have a role in unleashing epigenetic varia tion, given that cancerassociated mutants of adenomatous polyposis coli (APC), BRCA and p53 interact with epigenomecontrolling proteins. We propose that after regula tion of the epigenetic signature is relaxed, stochastic variation becomes the driving force in patterning the epigenome, allowing DNA methylation or chromatin structure to gradually diffuse away from its initial state. Natural selection within the host then allows each cancer to move differently, also leading to substantial epigenetic variation between a given cancer type across individuals or between metastases of a given cancer.
This epigenetic signature is constantly buffeted by stochastic variation, as if the ball is rocking randomly from side to side. The restoring force -that is, the network of genes that maintain epigenetic homeostasis -prevents the epigenetic signature from wandering too far from its equilibrium point in normal tissue. We can model this variation using an Ornstein-Uhlenbeck process (FIG. 2c) ; such processes are already used in biology for modelling selection pressure versus random genetic drift 116 . On the basis of this model, our argument that cancer involves a loss of regulation of the epigenome means that the restoring force is reduced or lost altogether (the positive feedback referred to above).
We generated simulated methylation lev els using this process (FIG. 2c) . Before carcino genesis, methylation levels have relatively low variability, oscillating stochastically around their equilibrium point. When the simulation reaches the carcinogenesis point, we reduced the restoring force in the process, flatten ing the Waddington valley (FIG. 2b) , and allowed the simulation to continue. The simulated methylation levels subsequently exhibited a random walk away from their previously wellordered profile. It is impor tant to note that the distance from the origi nal equilibrium point increases over time, but not directionally: instead it increases by a diffusive spreading of the epigenetic signature (FIG. 2c) .
We then applied our model to existing DNA methylation data from our previ ous work 7 , selecting a CpG from within a hypomethylated block as an example. The density plot of methylation values for nor mal, adenoma and cancer tissue at this CpG demonstrate the tight distribution in normal tissue, with a progressive relaxation from normal to adenoma to carcinoma (FIG. 2d) .
The simulated values match the actual data extremely well (FIG. 2d,e) . This model is intended to suggest the underlying behaviour that may explain the increased distance from the normal profile we observe in tumour cells over time. We have not studied this exhaustively, and only one CpG is used as an example of the type of stochastic process that might apply. There are two interesting implications of this suggested model. First, the increased variation over time shown in data and matched by the model supports the idea that disruption of epigenetic regula tion occurs at the earliest stages of cancer. Second, it shows that the idea of looking for a defined epigenetic signature for cancer is flawed. Rather, we should be looking for an antiprofile: that is, stochastic departure from a normal epigenetic signature.
Epigenetics and cancer hallmarks
Cancer is usually viewed as a complex group of multiple disorders that are mostly driven by somatic mutation and that involve the accre tion of ten proposed properties: enhanced proliferation, growth suppressor evasion, antiapoptosis, replicative immortality, angio genesis, inflammation, altered metabolism, genomic instability and metastasis signal ling 117 . We suggest that epigenetic disruption lies at the heart of all of these processes and that mutations enable and collaborate in these disruptions. The hallmark properties of can cer arise not only by mutation but also gener ally through stochastic epigenetic variation (as described above) and by natural selection of phenotypes that are advantageous to cancer cell survival and growth at the expense of the host. This is described graphically in FIG. 3 , in which the epigenome sits at the intersection of the environment, genetic mutation and tumour cell growth.
Epigenetic damage arises from carcino gens or diet (for example, methionine), as well as injury and inflammation (for exam ple, altered LOCKs and LADs in EMT, as described above). Errors in the mainte nance of the epigenome over time -that is, simply ageing -may also have a role in accumulating stochastic epigenetic damage. The mechanism for maintaining epigenetic integrity is damaged in either of two ways: through mutation in the genes that encode these mechanisms (TABLE 1) or through epi genetic modifications themselves in such genes (TABLE 2) resulting in positive feedback. Examples of epigenetic modifications that lead to positive feedback include epigenetic silencing of EZH2 and loss of imprinting (LOI) in colorectal cancer. This damaged epigenetic maintenance machinery leads to stochastic drift from a normal epigenetic set point (FIG. 2) and selection for cancer hall marks that give the cell a growth advantage at the expense of the host.
Some epigenetic modifications directly affect the hallmark properties of cancer; for example, shifts in the methylation boundaries at CGIs and CGI shores result in enhanced proliferation and metabolic change, and hypomethylated blocks lead to increased invasive potential 61 . In addition, shifting DNA methylation at CGI bounda ries leads to hypomethylated shores and the activation of cell cycle genes that are over expressed in cancer 7 , another cancer hallmark. In this case loss of DNA methy lation, which seems to be a ground state for embryonic stem cells 24 , seems to promote gene expression, normally in development and abnormally in cancer. Similarly, LOI can directly change the balance between apoptosis and proliferation 118, 119 (FIG. 3) .
Epigenetic dysregulation occurs very early in cancer. For example, DNA methy lation is altered in the normal tissue of cancer patients, and these changes increase with age, suggesting a mechanism by which cancer frequency increases in an agedependent manner [120] [121] [122] (FIG. 3) . A second example is LOI of insulinlike growth factor 2 (IGF2) in colorectal cancer, in which the normally silent allele becomes activated, leading to a double dose of this mitogen. In colorectal cancer, LOI of IGF2 is found in both the tumours and the normal tissue of affected patients 123 , and induced LOI of Igf2 in mice doubles the frequency of tumour development 124 . A third example is that Barrett's oesophagus shows epigenetic modifications long before pro gression to overt malignancy 114 . Epigenetic modifications, particularly increased hetero geneous outlier variability in DNA methy lation, are also predictive of malignant change in cervical cancer 125 .
Where do mutations fit into this process? We have previously suggested that evolution may favour mechanisms through genetic selection that allow for epigenetic hetero geneity by providing a selective advantage in a changing environment 113 . We suggest a similar mechanism might occur in cancer: that is, selection for epigenetic plasticity itself. More generally, we suggest that the initial dysregulation of the epigenome col laborates with crucial mutations to provide the phenotypic variation that allows the selection of the hallmark properties of can cer. There is interplay between epigenetic dysregulation, which provides the phenotypic heterogeneity that generates the hallmark properties of cancer and that potentially alters the mutation rate, and genetic muta tions, which directly alter genes and path ways to confer hallmark properties of cancer, as well as enabling and assisting in epigenetic dysregulation (FIG. 3) . Furthermore, the epige netic changes themselves may contribute to increased mutation frequency.
We note that these mutations in epi genetic controlling genes generally occur in two types of tumours: haematopoietic malignancies and rare solid tumours (childhood solid tumours or aggressive subtypes of common adult solid tumours). The implication of this observation, which seems fairly well supported by a great deal of sequencing data, is that primary epige netic modifications are a more prominent mechanism for cancer progression in com mon solid tumours than are mutations in epigenetic modifiers. The converse of this argument is that mutations in epigenetic modifiers have extremely strong effects on cellular behaviour, which is consist ent with the profound aggressiveness of such tumours and their relative rarity. Haematopoietic malignancies are consistent with this view, as they commonly exhibit mutations in epigenetic modifier genes but arise almost completely progressed (that is, widely disseminated) compared with solid tumours. Even lymphomas, which can be relatively indolent for long periods, are more aggressive when associated with mutations in epigenetic modifiers.
Note that we do not exclude a primary role for mutations in conferring the hall mark properties of cancer, and in fact we believe that they do. We simply suggest that the epigenome is not relegated to merely a surrogate for mutation but rather that it has important nonlocal ramifications. Limiting our understanding of epigenetics in the context of cancer to the genecentric view may neglect valuable insights into how cancer causes a general disruption of genetic regulation through the epigenome. With that in mind, even genes that are not normally thought to have a primary epi genetic role may have a strong interaction with the epigenome. For example, BRCA2, which at one time was thought to be a his tone acetyltransferase 126 , is actually a bind ing partner of the histone acetyltransferase PCAF (also known as KAT2B) 127 . SMAD4 is mutated in pancreas adenocarcinoma and has been shown to be an important driver of this cancer type, but it also interacts with chromatin remodellers 83 . p53 directly interacts with DNMT1, which act together to control the expression of antiapoptotic genes 128 . The epigenome can also be indi rectly affected through pathways that are commonly mutated in cancer that can affect the expression level of epigenetic con trolling proteins. Examples include the reg ulation of histone deacteylase 2 (HDAC2) 129 and DNMT1 (REF. 130 ) by mutations of the WNT-βcatenin pathway, such as APC mutations in colorectal cancer. In fact, the protein stability of DNMT1, rather than its expression, may be altered by the PI3K-AKT pathway so that levels of the DNMT1 pro tein (and not mRNA) are changed without new expression 131 .
Implications for diagnosis and therapy
Viewing epigenetic dysregulation itself as a common driver of cancer progression has important implications for cancer diagno sis and therapy. For diagnosis it suggests a promising approach for identifying patients very early in the course of disease, and for therapy it suggests novel targets that could be the focus of therapeutic intervention early or even before the development of overt cancer.
In epigenetic detection, a great deal of effort has been invested in identifying CGI hypermethylation, with limited success 49 . We suggest that this is because an implica tion of the recent wholegenome epigenetic work shows that departure from a normal profile is more pathognomonic than a specific cancer epigenetic signature. For example, septin 9 (SEPT9) was reported to be a sensitive and specific serumbased marker for colorectal cancer 132 . However, a case-control study carried out indepen dently of the commercial developer showed 90% sensitivity and 88% specificity for colorectal cancer but only 71% sensitivity for early cancers and 12% sensitivity for adenomas 133 , and therefore this marker is not useful for early screening. Similarly, methylation of bone morphogenetic pro tein 3 (BMP3), eyes absent homologue 2 (EYA2), ALX homeobox 4 (ALX4) or vimentin (VIM) was found in 66%, 66%, 68% and 72%, respectively, of primary colorectal cancers but in 7%, 5%, 11% and 11%, respectively, of normal mucosa 134 . One notable exception to the disappointing history of epigenetic detection of cancer is glutathione Stransferase pi 1 (GSTP1) in prostate cancer 135 , and this is probably because this particular gene has a crucial role in the early stage of the disease rather than being an indicator of epigenetic dysregulation per se.
If a detection scheme was developed on the basis of antiprofiling instead, a much higher sensitivity and predictive value might be achieved. Consistent with this idea, Teschendorff and colleagues 125, 136 recently showed that the DNA methylation variability was more predictive of cancer progression than mean changes in DNA methylation in both cervical 125 and breast 136 cancers. This test can differentiate between normal and neoplastic cervical tissue with 95% sensitivity and 78% specificity 125 . In fact, this test is predictive using tissue taken before the development of cervical neoplasia; neoplasia development within 3 years of sample collection is predictable with a 71% sensitivity and 50% specificity 125 . DNA methylation instability at specific loci is predictive of survival in endometrial, ovar ian, cervical and breast cancers, emphasiz ing the usefulness of epigenetic instability in chemoresistance 136 . Such an approach could even be used in screening patients for early cancer: epigenetic antiprofiling of tumour cells using a sophisticated digital PCRbased approach has already shown considerable utility for the early diagnosis of colorectal cancer in stool 137 . The methylation signature at specific CGIs can also suggest specific forms of tailored therapy, as in O The epigenome sits at the intersection of the environment, genetic mutation and tumour cell growth. Environmental factors, such as carcinogens or diet, as well as injury and inflammation, cause epigenetic reprogramming. The epigenome also accumulates damage stochastically and through ageing. The machinery for maintaining epigenetic integrity can be stably disrupted in either of two ways: by mutation or by epigenetic change itself with positive feedback. Examples of mutation include epigenetic regulator mutations (TABLE 1) , whereas examples of epigenetic change include loss of imprinting (LOI) of insulin-like growth factor 2 (IGF2) in colorectal carcinogenesis, enhancer of zeste homologue 2 (EZH2) silencing in prostate cancer (TABLE 2) and overexpression of reprogramming factors. The disruption of epigenetic integrity maintenance leads to the loss of epigenetic regulation and stochastic drift from a normal set point, followed by selection for cellular growth at the expense of other cells (FIGS 1,2) . Some epigenetic modifications, such as shifting methylation boundaries at CpG islands and shores, lead to metabolic change and enhanced proliferation. Others, such as hypomethylated blocks, lead to increased invasion. Still others, such as LOI, directly change the balance between apoptosis and proliferation. Canonical mutations, such as in adenomatous polyposis coli (APC) and TP53 (which encodes p53), directly affect cancer hallmarks but can also cause epigenetic dysregulation. Similarly, epigenetic disruption, such as regional hypomethylation or CpG hypermethy lation, can lead to increased chromosomal rearrangements and mutations, respectively. Instability of CpG island methylation boundaries also contributes to epigenetic dysregulation, allowing for selection in response to the cellular environment for cellular growth advantage at the expense of the host. ARID1A, AT-rich interactive domain-containing protein 1A; KLF4, Krüppel-like factor 4; MLL, mixed lineage leukaemia; TET2, tet methylcytosine dioxygenase 2.
for glioma 138 . However, other hypermethy lated CGI markers have not shown a high degree of sensitivity or specificity for cancer or for key phenotypes, such as drug resist ance, although such efforts are still ongo ing 139 . In these cases DNA methylation is being used as a surrogate measure of gene expression and/or gene regulation.
In the case of haematological malignan cies, in which mutations in epigenetic regu lators are most frequent (TABLE 1) , therapy targeted towards these pathways is already quite promising, including EZH2 inhibitors for lymphoma 140, 141 , inhibitors of mutant IDH1 for acute myeloid leukaemia and myelodysplasia 142 , and HDAC inhibitors for cutaneous T cell lymphoma 108 . Additionally, a clever approach has been taken to inhib iting DOT1L, which is not mutated itself but which is a common target of MLL translocations 143 . In our view, the most exciting poten tial application of this model of epige netic dysregulation as a common driver throughout cancer progression is the potential for targeted chemoprevention. Currently, chemoprevention involves either nutritional recommendations or the use of nonprescription agents such as cyclooxygenase 2 (COX2; also known as PTGS2) inhibitors targeted towards individuals with a high risk of develop ing colorectal cancer, such as those with a strong family history of colorectal can cer 144, 145 . The approach to chemopreven tion is far more limited than in cardiology, in which chemoprevention with prescrip tion medication (statins) is extremely effective at preventing heart disease 146 ; this was a controversial approach when statins were first introduced for widespread use in the population. But what if we could iden tify the epigenetic disruption in patients before neoplastic growth even begins (as has been shown for cervical cancer 125 )? Then we might treat such patients with specific inhibitors even before they develop cancer. Similarly, LOI of IGF2 is associated with an increased frequency of colorectal cancer 123 and may be associated with gastric cancer risk 147 . LOI of IGF2 also substantially increases the frequency of colon preneoplastic aberrant crypt foci in mice treated with the carcinogen azoxy methane, and inhibition of signalling at the IGF2 receptor reduces the incidence of neoplasms to a level even lower than that found in mice with normal Igf2 imprint ing 148 . Thus, we might be able to identify disruption of the epigenome or even the risk of such disruption through epigenetic or genetic testing before cancer arises, and then treat patients preventively to reduce cancer incidence. This seems to us to be a potentially far more effective mechanism for reducing cancer mortality than the treatment of latestage disease, and it would argue strongly for an epigenomecentred approach.
